PMV Pharmaceuticals has been granted a patent for compounds that bind mutant p53 proteins and enhance their wild-type p53 activity. The composition includes molecules with deuterium atoms, each having a mass of at least 1 µg. GlobalData’s report on PMV Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on PMV Pharmaceuticals, Targeted cancer therapy was a key innovation area identified from patents. PMV Pharmaceuticals's grant share as of May 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11963953B2) discloses a composition comprising a population of molecules with a mass of at least 1 µg, where at least 10% of the molecules contain a deuterium atom. The molecules in the composition are compounds of Formula (I), with specific variations in the substituents R1, R2, and R4. The patent also includes methods for inducing apoptosis in cells and treating cancer by administering the composition, particularly targeting p53 mutants like p53 Y220C.
The patent further details the method of inducing apoptosis in cells by contacting them with the composition, leading to increased binding ability of p53 mutants to DNA, conformational changes, and enhanced stability of biologically-active conformations. The therapeutic effectiveness of the composition in treating cancer, including breast and lung cancer, is highlighted, with administration routes ranging from intravenous to oral or intratumoral. The compound of Formula (I) is crucial in increasing the stability of p53 mutants and has an SC150 value of less than 1 mM, making it a promising candidate for cancer treatment. Additionally, the patent includes variations in the structure of the compound within the composition, emphasizing the high percentage of molecules containing the specific structure for enhanced efficacy.
To know more about GlobalData’s detailed insights on PMV Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
